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Abstract
Acquired drug resistance prevents cancer therapies from achieving stable and complete responses.
1
 Emerging evidence implicates a key role for nonmutational drug resistance mechanisms 
underlying the survival of residual cancer “persister” cells.2-4 The persister cell pool constitutes a 
reservoir from which drug-resistant tumours may emerge. Targeting persister cells therefore 
presents a therapeutic opportunity to impede tumour relapse.5 In an earlier report, we found that 
cancer cells in a high mesenchymal therapy-resistant cell state are dependent on the lipid 
hydroperoxidase GPX4 for survival.6 Here, we describe the discovery that a similar therapy-
resistant cell state underlies the behavior of persister cells derived from a wide range of cancers 
and drug treatments. Consequently, we show that persister cells acquire a dependency on GPX4. 
We demonstrate that loss of GPX4 function results in selective persister cell ferroptotic death in 
vitro and prevents tumour relapse in vivo. These findings support targeting GPX4 as a therapeutic 
strategy to prevent acquired drug resistance.
We sought to identify therapeutically exploitable vulnerabilities in an experimental model of 
minimal residual disease, drug-tolerant persister cells. Persister cells, which are present 
across a wide range of tumour types, survive cytotoxic exposure to targeted therapy or 
chemotherapy through poorly understood reversible, nonmutational mechanisms.2 We 
focused our initial work on the HER2-amplified breast cancer line BT474 which, upon 
treatment for nine or more days with cytotoxic concentrations of lapatinib, reveals a small 
population of quiescent surviving persister cells (Fig. 1a). Removal of lapatinib allows the 
persister cells to regrow and re-acquire sensitivity to lapatinib. Subsequent lapatinib 
treatment re-derives persister cells. The reversibility of BT474 persister cell drug resistance, 
which is also observed in other persister cell models2 including A375 melanoma (Extended 
Data Fig. 1a), is indicative of a nonmutational resistance mechanism.
To identify cellular processes that may represent selective dependencies in persister cells, we 
performed RNAseq on BT474 persister cells and drug naïve parental cells (Extended Data 
Tables 1, 2 and Supplementary Tables 1-4). In persister cells, we observed upregulation of 
stemness markers CD133 and CD44 which corroborated earlier observations in other 
persister cell models2 (Extended Data Table 1). We also observed upregulation of 
mesenchymal markers and downregulation of epithelial markers (Extended Data Table 1), 
and this encouraged us to further explore the role that mesenchymal state biology may play 
in persister cell therapy resistance. Furthermore, a broad downregulation of antioxidant 
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gene-expression in persister cells, including Nrf2 target genes, directed our attention toward 
possible persister cell vulnerabilities in oxidative stress defense mechanisms (Extended Data 
Fig. 1b and Extended Data Table 2).
We recently reported that cancer cells in a high mesenchymal therapy-resistant state are 
selectively sensitive to ferroptosis, an oxidative form of cell death which can be induced by 
inhibition of the lipid hydroperoxidase GPX4.6 We included GPX4 inhibitors within a 
diverse collection of compounds screened against BT474 parental and persister cells and 
found GPX4 inhibitors RSL3 and ML210 to be among the compounds most selectively 
lethal to persister cells, with minimal effect on parental cells or nontransformed MCF10A 
cells (Fig. 1b, c, and Extended Data Fig. 1c). Given the observed phenotypic and gene-
expression similarities between persister cells from different cancer types,2-4,7 we wondered 
whether sensitivity to GPX4 inhibition might be a general persister cell vulnerability. 
Remarkably, we found that sensitivity to GPX4 inhibition extended beyond BT474 persister 
cells to a variety of other persister cell models (Fig. 2a-h and Extended Data Fig. 1d). In 
each case, we found the parental cells to be far less sensitive to GPX4 inhibitors (Fig. 2a-h). 
We also observed a differential sensitivity of persister cells, although to a lesser extent, to the 
ferroptosis inducer erastin which acts upstream of GPX4 by depleting GPX4 cofactor 
glutathione (Extended Data Fig. 1e, f).8
We further confirmed the GPX4 dependency of persister cells using GPX4 knockout (KO) 
A375 melanoma cells (Fig. 2i, j, Extended Data Fig. 1g and Supplementary Data). A 
hallmark of ferroptosis is the accumulation of lipid hydroperoxides, and lipophilic, small-
molecule antioxidants have been shown to rescue cells from ferroptosis.9-11 Upon 
withdrawal of the ferroptosis-rescuing lipophilic antioxidant ferrostatin-1, we observed that 
A375 GPX4 KO, but not GPX4 wild type (WT), persister cells undergo ferroptotic death 
(Fig. 2i).6 In contrast, GPX4 loss has minimal effect on parental A375 cell viability (Fig. 2j). 
Furthermore, we found that GPX4 inhibitors are not synergistic with lapatinib treatment of 
parental BT474 cells, demonstrating that GPX4 dependence is specific to the persister cell 
state (Extended Data Fig. 1h). In addition, though p53 can regulate ferroptosis sensitivity,12 
we found that persister cells are GPX4 dependent regardless of p53 status (Fig. 2). These 
findings support the compelling hypothesis that GPX4 is a selective dependency of a drug-
resistant persister cell state that is shared by cancer cells from many lineages subjected to 
diverse therapeutic regimens.
To test whether diverse persister cell types undergo canonical ferroptosis10 upon GPX4 
inhibition, we treated persister cells with a series of ferroptosis rescue compounds. We found 
that co-treatment with the lipophilic antioxidants ferrostatin-1 or liproxstatin-1 rescued 
various persister cell types from GPX4 inhibition (Fig. 3a and Extended Data Fig. 2a-c). 
Ferroptosis is an iron-dependent process, and although persister cells have less labile iron 
than parental cells (Extended Data Fig. 2d), we observed that iron is nonetheless essential 
for GPX4 inhibitor-induced persister cell death because iron chelation with deferoxamine 
(DFO) partially rescues persister cells (Fig. 3b). Furthermore, consistent with the established 
role for lipoxygenase-catalyzed lipid hydroperoxidation for ferroptosis, we observed that 
treatment with lipoxygenase inhibitors rescued persister cells from GPX4 inhibition (Fig. 3c 
and Extended Data Fig. 2a, b). Lipid hydroperoxides must be transported by the lipid 
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transporter SCP2 for cell death to occur.13,14 Accordingly, we found that persister cells were 
protected from GPX4 inhibition by chemical inhibition of SCP2 (Fig. 3d and Extended Data 
Fig. 2a, b). Also, in agreement with the non-apoptotic, caspase-independent nature of 
ferroptosis, we found that persister cell death from GPX4 inhibition is not rescued by the 
pan-caspase inhibitor Z-VAD-FMK (Fig. 3e and Extended Data Fig. 2a-c). These ferroptosis 
characteristics were also observed in A375 GPX4 KO persister cells upon removal of 
ferrostatin-1 (Fig. 3f). Taken together, these observations indicate that GPX4 inhibition 
induces canonical ferroptosis in persister cells.
Based on our observation that antioxidant genes are downregulated in persister cells 
(Extended Data Fig. 1b and Extended Data Table 2), we hypothesized that there may be a 
disabled antioxidant program which contributes to the sensitivity to ferroptosis. Glutathione 
and NADPH are two reducing cofactors that have been demonstrated to protect cells from 
the toxic effects of lipid peroxidation and prevent ferroptosis.10,15,16 We found that persister 
cells have markedly decreased levels of both reducing cofactors (Fig. 4a, b and Extended 
Data Fig. 3a). This is consistent with our observation that persister cells have downregulated 
expression of glutathione and NADPH biosynthesis genes (Extended Data Table 2). Also, 
replacement of glutathione via treatment with glutathione metabolic precursor N-acetyl 
cysteine (NAC) partially rescues persister cells from ferroptosis (Extended Data Fig. 3b). 
Persister cells have a specific sensitivity to lipid peroxidation, rather than general sensitivity 
to oxidative stress, because persister cells are not rescued from GPX4 inhibition by 
antioxidants ebselen and EUK134 (Extended Data Fig. 3b), exhibit only modestly increased 
sensitivity to endogenous reactive oxygen species (ROS) induced by DMNQ treatment 
(Extended Data Fig. 3c), and are relatively insensitive to inhibition of an unrelated 
antioxidant gene, SOD1 (Extended Data Fig. 3d). These findings indicate that global 
downregulation of Nrf2 targets and other antioxidant genes, and decreased glutathione and 
NADPH act to impair persister cell lipid peroxidation defense and contribute to a 
dependence on GPX4 for survival.
Consistent with a disabled lipid peroxidation defense, we observed that after one hour of 
GPX4 inhibition and prior to any cell death, there is a drastic elevation in 2′,7′-
dichlorofluorescein (DCF) staining of ROS which indicates lipid peroxidation in persister 
cells but not parental cells (Fig. 4c, and Extended Data Fig. 3e). Furthermore, upon lipid 
hydroperoxide accumulation, free reduced glutathione levels are expected to decrease 
because reduced glutathione covalently ligates, via glutathione-S-transferase catalyzed or 
non-enzymatic glutathionylation, to oxidized products of lipid peroxidation such as 
aldehydes.17 Consistent with this, we observed a decrease in reduced glutathione levels 
specifically in persister cells immediately after GPX4 inhibition that mirrored the increase in 
DCF staining (Fig. 4a and Extended Data Fig. 3a). Interestingly, a recent study found that 
persister cells are sensitive to the aldehyde dehydrogenase inhibitor disulfiram.3 While 
disulfiram was shown to cause apoptosis rather than ferroptosis, and is not rescued by 
ferrostatin-1 (Extended Data Fig. 3f), the persister cell sensitivity to disulfiram may be 
reflective of the broader disabled antioxidant program.
We reasoned that an effective GPX4 inhibitor could potentially be used in a clinical setting 
to prevent tumour relapse. To test this possibility in a preclinical model, we developed an 
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A375 melanoma xenograft model wherein tumours respond and relapse upon treatment with 
dabrafenib and trametinib. Because neither RSL3 nor ML210 are systemically bioavailable, 
we instead adopted a recently developed genetic strategy6 to test GPX4 dependence of 
residual tumours in vivo. Using GPX4 KO or GPX4 WT A375 cells (Extended Data Fig. 1g 
and Supplementary Data), we formed xenograft tumours in nude mice. We then treated the 
mice with dabrafenib and trametinib to shrink the tumours while concurrently dosing the 
mice with ferrostatin-1 to mask any effects of GPX4 deletion before or during the initial 
response to drug treatment. Once tumours had been reduced to their minimal volume, 
ferrostatin-1 was withdrawn, unmasking the GPX4 KO effect in these residual tumours. 
Upon further dosing of mice with dabrafenib and trametinib, without ferrostatin-1, the 
GPX4 WT tumours relapsed and the GPX4 KO tumours did not (Fig. 4d and Extended Data 
Fig. 3g). In contrast, parental A375 GPX4 KO and WT cells both formed tumours without 
ferrostatin-1 equally well (Extended Data Fig. 3h). Taken together, these A375 melanoma 
xenograft data are consistent with an essential role for GPX4 in residual A375 tumours in 
vivo.
Our data reveal that co-treatment of cancer cells with a targeted therapy or chemotherapy 
agent together with a GPX4 inhibitor effectively reduces the residual persister cell pool. 
However, co-treatment with multiple drugs often results in increased toxic side effects that 
can compromise patient safety and treatment efficacy. Interestingly, we found that 
pretreatment of BT474 parental cells with RSL3 alone for twenty-four hours decreases the 
number of persister cells remaining after subsequent lapatinib treatment (Fig. 4e). This 
finding is consistent with recent reports demonstrating that persister cells may preexist prior 
to drug treatment.3,18 We also observed that BT474 persister cells allowed to regrow after 
washout of lapatinib retain their full sensitivity to RSL3 for at least two weeks but for less 
than two months (Fig. 4e and Extended Data Fig. 3i), indicating that the disabled antioxidant 
program in persister cells is not immediately repaired upon drug removal and regrowth. 
These findings demonstrate that pre- or post-treatment with GPX4 inhibitors, rather than co-
treatment, may be adequate to deplete the pool of persister cells that survive targeted therapy 
or chemotherapy. This staggered treatment strategy may be clinically beneficial in 
maximizing efficacy while minimizing the potential increase in toxicity that might be 
anticipated from simultaneous co-treatment with two agents.
Nonmutationally drug-tolerant persister cells have recently gained attention for their 
potential role in acquired drug resistance where they may constitute a reservoir of surviving 
cells from which fully drug-resistant cells eventually emerge to cause tumour relapse.2,4,5 
Here we have shown that GPX4 inhibition is a promising strategy to selectively eradicate 
this residual cell reservoir(Extended Data Fig. 3j). While existing GPX4 inhibitors, 
including RSL3 and ML210, are valuable tool compounds in cell culture settings, their poor 
pharmacokinetic properties preclude their systemic use in vivo. Given the therapeutic 
promise for inducing ferroptosis in persister cells and drug-resistant cancers,6,19 the 
development of a potent bioavailable GPX4 inhibitor is an urgent priority. Because GPX4 
genetic deletion is lethal in adult mice,13,20 further study will be needed to determine 
whether a suitable therapeutic window exists for treatment with GPX4 inhibitors. In 
summary, we have found that GPX4 inhibition results in ferroptotic death in cancer persister 
cells across many lineages, presenting a novel strategy to prevent tumour relapse.
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Methods
Cell culture
HER2 amplified breast cancer BT474 (ATCC), EGFR mutant non-small cell lung cancer 
PC9 (Sigma-Aldrich), and Kuramochi ovarian cancer (JCRB) cells were cultured in 
RPMI-1640 medium, and BRAF mutant A375 melanoma (ATCC) cells were cultured in 
Dulbecco's Modified Eagle Medium, each supplemented with penicillin, streptomycin and 
10% FBS. A375 GPX4 KO cells were cultured in the presence of 2 μM ferrostatin-1 unless 
otherwise noted. MCF10A (ATCC) cells were cultured in Mammary Epithelial Cell Growth 
Medium supplemented with bovine pituitary extract, gentamycin, amphotericin B (Lonza 
MEGM BulletKit), and 100 ng/mL cholera toxin (Sigma). Each cell line was maintained in a 
5% CO2 atmosphere at 37°C. Cell line identities were confirmed by STR fingerprinting and 
all were found to be negative for mycoplasma using the MycoAlert kit (Lonza).
Persister cell derivation and treatments
Persister cells were derived from treatment of HER2 amplified breast cancer BT474, EGFR 
mutant non-small cell lung cancer PC9 or Kuramochi ovarian cancer cells with 2 μM 
lapatinib, 2 μM erlotinib, or co-treatment with 10 μM carboplatin and 100 nM paclitaxel, 
respectively, for at least nine days with fresh drug added every three days. A375 persister 
cells were derived from nine or more days of 2 μM vemurafenib (Fig. 2i), 25 μM 
vemurafenib (Extended Data Fig. 1a), 1 μM dabrafenib and 100 nM trametinib (Fig. 3f and 
Extended Data Fig. 2a, b), or 2 μM dabrafenib and 200 nM trametinib (Fig. 2b, f). A375 
GPX4 KO cells were maintained in media with 2 μM ferrostatin-1 during persister cell 
derivation with drug. Chemotherapy-derived BT474 persister cells were similarly derived 
from co-treatment with 25 μM carboplatin and 1.25 nM paclitaxel (Extended Data Fig. 1d). 
Unless otherwise noted, small-molecule inhibitors were added to prederived persister cells in 
twelve well tissue culture plates that were maintained under constant drug exposure 
throughout subsequent small-molecule inhibitor treatment. Cell viability was assessed using 
CellTiter Glo (Promega) after three days of small-molecule treatment, or three days after 
ferrostatin-1 removal in the case of A375 GPX4 KO cell experiments, unless otherwise 
noted.
For testing RSL3 pretreatment prior to persister cell derivation and RSL3 treatment on cells 
regrown from persister cells (Fig. 4e), the following experimental setup was used. Fig. 4e, 
left, BT474 parental cells were pretreated for 24 hours with 1 μM RSL3 alone, then RSL3 
was removed and persister cells were subsequently derived from two weeks of treatment 
with 2 μM lapatinib alone followed by cell viability assay. For Fig. 4e, middle and right, 
prederived BT474 persister cells from 2 μM lapatinib were allowed to regrow upon removal 
of lapatinib for 15 days (middle) or 63 days (right) and then were treated for three days with 
1 μM RSL3 alone followed by cell viability assay.
Chemicals
(Z)-4-Hydroxytamoxifen, altretamine, baicalein, BWA4C, deferoxamine mesylate salt 
(DFO), erlotinib hydrochloride, ferrostatin-1, gossypol, HA14-1, hydroxychloroquine, 
liproxstatin-1, ML210, PBIT, salinomycin, trigonelline hydrochloride, tunicamycin, zileuton 
Hangauer et al. Page 6
Nature. Author manuscript; available in PMC 2018 May 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
and Z-VAD-FMK were purchased from Sigma-Aldrich. ABT-263, ABT-737, dabrafenib, 
paclitaxel, canertinib, fluvastatin, GSK2110183, GX15-070, LBH589, 1S,3R-RSL3 (RSL3), 
romidepsin, saracatinib, trametinib, trichostatin A, TW-37 and vorinostat were purchased 
from Selleck Chemical. Mifepristone, pladienolide B, SB-431542, vemurafenib and 
XAV939 were purchased from Santa Cruz Biotechnology. Compound A (Mirk inhibitor), 
erastin, MIM1 and SP600125 were purchased from EMD Millipore. SCPI-2 and SCPI-4 
were purchased from ChemBridge. Metformin and PD146176 were purchased from Enzo 
Life Sciences. AEW541 and JQ1 were purchased from Cayman Chemical. WEHI-539 was 
purchased from MedChem Express. Everolimus was purchased from Cell Signaling 
Technology. 17-DMAG was purchased from Biotang USA. Herboxidiene was purchased 
from Apollo Scientific. Sorafenib tosylate was purchased from AK Scientific. Spliceostatin 
A was purchased from AdooQ Bioscience. Lapatinib ditosylate was purchased from LC 
Laboratories. Nordihydroguaiaretic acid (NDGA) was purchased from Acros Organics. 
Carboplatin was purchased from Hospira or Sigma. All chemicals were stored as stock 
solutions in DMSO (Sigma-Aldrich) or nuclease-free water (Life Technologies).
RNAseq library preparation
To generate BT474 persister cells for RNAseq, BT474 cells were plated in five 15 cm tissue 
culture plates per replicate, for three replicates, and were allowed to reach 75% confluency 
before being treated with 2 μM lapatinib for nine days. Simultaneously, parental BT474 cells 
were cultured for nine days in lapatinib-free media in a 15 cm tissue culture plate for each of 
two replicates. 2 million persister or parental cells were used per replicate for RNA isolation. 
RNA was isolated using Trizol (Life Technologies), following the manufacturer's 
instructions. RNA samples were quantified using a NanoDrop (ThermoFisher), and RNA 
integrity was determined using a RNA 6000 Nano Kit (Agilent) on an Agilent 2100 
Bioanalyzer. All RNA samples had a measured RNA Integrity Number (RIN) > 9.3. RNA 
samples were sent to the UC Davis Genome Center for non-strand specific polyA-
enrichment, Illumina library preparation including multiplex barcodes and RNAseq across 
six lanes of an Illumina HiSeq 2000 instrument. 145 million to 160 million single end, 50 
base pair reads were obtained per replicate.
RNAseq data analysis
Fastq sequence files were aligned to hg18 using TopHat v2.0.6, allowing only uniquely 
mapped reads with the -g 1 option. Differential expression testing and assignment of FPKM 
and fold change values to genes was performed with CuffDiff v2.0.2, comparing the two 
BT474 parental cell replicates to the three BT474 persister cell replicates. For CuffDiff, 
quartile normalization and -compatible-hits-norm options were used to assign reads to a 
GTF file containing all human RefSeq NM and NR genes which was downloaded from the 
UCSC Genome Browser and converted into a CuffDiff readable format using Cuffcompare 
as described in the Cufflinks manual.
The set of genes with minimum FPKM > 1 in either parental cells or persister cells, greater 
than two-fold upregulation or downregulation in persister cells relative to parental cells, and 
significant FDR corrected p value (q < 0.05) as calculated by CuffDiff were used for Core 
Analysis with Ingenuity Pathway Analysis (IPA) software to generate IPA results for 
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Canonical Pathways, Upstream Regulators, and Functions (Supplementary Tables 2-4). 
Analysis of differential expression among genes within previously established panels of 
mesenchymal and epithelial marker genes21 (Extended Data Table 1) and human antioxidant 
genes22 (Extended Data Fig. 1b) was also performed using FPKMs and fold changes 
calculated by CuffDiff.
Chemical inhibitor screens
BT474 cells were seeded in duplicate twelve well tissue culture plates and were allowed to 
reach 75% confluency. To derive persister cells, each well was treated with 2 μM lapatinib 
for nine days, with fresh media containing 2 μM lapatinib added every three days. Small-
molecule inhibitors at 1 μM concentration were then added in lapatinib-containing media 
and, following five days of incubation, each well was measured using CellTiter Glo reagent. 
CellTiter Glo measurements were made by transferring 200 μL of the CellTiter Glo solution 
per well into Costar 96 well clear flat bottom plates for readout using a Promega GloMax 
Explorer luminometer. CellTiter Glo luminescent signal was normalized to negative control 
wells by calculating the ratio of luminescence signal in the test versus negative control wells. 
Negative control wells contained media with 2 μM lapatinib but no additional chemical 
inhibitors. Each small-molecule inhibitor was also tested at 1 μM concentration in parental 
BT474 cells in 12 well plates, where cells were seeded in duplicate wells at 25% confluency 
and treated with chemical inhibitors. Following incubation for five days, cell viability was 
measured with CellTiter Glo.
CRISPR-mediated GPX4 deletion
Guide RNAs targeting the first exon of human GPX4 were designed using the CRISPR 
Design tool (Zhang lab, MIT). pX330 (Zhang lab, MIT) expression plasmids encoding the 
single guide RNAs 5′-CACGCCCGATACGCTGAGTG-3′ (for GPX4 KO clone 1) or 5′-
CTTGGCGGAAAACTCGTGCA-3′ (for GPX4 KO clone 2) and spCas9 were generated 
and transfected into A375 cells in the presence of 2 μM ferrostatin-1 using Lipofectamine 
3000 (Life Technologies). The cells were subjected to two rounds of transfection. In the first 
round, the CRISPR plasmids were co-transfected with a vector encoding mCherry and 
puromycin resistance. 24 hours after the transfection, the cells were selected with 1 μg/mL 
puromycin for three days. The selected cells were expanded and transfected again with the 
pX330 CRISPR constructs and a pMax-GFP reporter. 24 hours after the transfection, the 
cells were sorted and the GFP-positive, mCherry-negative cells were retained. Cells were 
then transferred into 96 well plates at ∼1 cell/well and expanded as clones. Genomic DNA 
was extracted from all clones with the NucleoSpin Blood kit (Macherey-Nagel). The GPX4 
target sites were amplified from 100 ng of genomic DNA with Phusion DNA Polymerase 
(NEB) with primers For (5′-GTAAAACCGGACCAGAAGTACAAG-3′) and Rev (5′-
CCCACCTGCTTCCCGAACTG-3′). Purified PCR products were TOPO cloned (Life 
Technologies) and sequenced with primer M13F (Quintara). 5 TOPO colonies from each 
clone were sequenced to confirm frameshifts in GPX4.
A375 GPX4 KO clones 1 and 2 were confirmed to lack GPX4 protein by western blot. For 
this, 3 million cells were seeded in 10 cm tissue culture plates and grown to 75% confluence, 
and the following day, cells were trypsinized, washed with PBS, and lysed using RIPA 
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buffer (Thermo Scientific) supplemented with phosphatase inhibitor (Sigma) and protease 
inhibitor (Sigma). Lysates were centrifuged at 13,000 rpm at 4°C for twelve minutes, and the 
protein concentration of the supernatant was determined using the Bio-Rad Protein Assay. 
40 μg of protein per sample was mixed with sample buffer (Bio-Rad) and denatured at 95°C 
for five minutes. Samples were separated by SDS-PAGE (NuPage 4–12% Bis-Tris Gel, Life 
Technologies), run with BioRad Precision Plus Protein Kaleidoscope ladder, and transferred 
to a nitrocellulose membrane using an iBlot system (Life Technologies). Membranes were 
blocked with 5% BSA for one hour at room temperature, and then incubated with either a 
1:1000 dilution of anti-GPX4 (rabbit) polyclonal Ab (Abcam, ab41787) or 1:5000 dilution 
of anti-β-Actin (mouse) mAb (Sigma, A5441) at 4°C overnight. LICOR secondary 
antibodies were then incubated with the membrane for one hour at room temperature, and 
the membrane was imaged using the LICOR Odyssey Imaging System.
Glutathione and NADPH measurements
NADP/NADPH-Glo and GSH-Glo assay kits (Promega) were used to measure NADPH 
levels in 20,000 cells and glutathione levels in 50,000 cells per replicate following 
manufacturer's instructions. To measure total glutathione (GSH + GSSG), oxidized 
glutathione (GSSG) was reduced by incubating test samples with 500 μM tris(2-
carboxyethyl)phosphine (TCEP) for 10 minutes prior to luminescence measurement, 
following the manufacturer's instructions. Each assay was read out using a Promega GloMax 
Explorer luminometer.
Intracellular reactive oxygen species measurements
BT474 cells plated in replicate 10 cm tissue culture plates were treated with 2 μM lapatinib 
for at least nine days, with fresh media added every three days, to derive persister cells. For 
cells re-grown from persister cells (Extended Data Fig. 3i), lapatinib was subsequently 
removed from persister cells and fresh lapatinib-free media was replaced every three days 
for fifteen days. Then, for both the persister cell experiments (Fig. 4c and Extended Data 
Fig. 3e) and regrown cell experiments (Extended Data Fig. 3i), cells were treated with 1 μM 
RSL3 or ML210 for one hour. RSL3 or ML210 was removed and cells were trypsinized. 
100,000 cells were pelleted per replicate, and cell pellets were resuspended in full media 
containing 25 μM 6-carboxy-2′,7′-dichlorodihydrofluorescein diacetate, di(acetoxymethyl 
ester) (carboxy-DCFDA, acetoxymethyl ester) (Thermo Fisher Scientific) in HBSS with 1% 
FBS. After thirty minutes of incubation with DCF dye, cells were pelleted again, 
resuspended in HBSS with 1% FBS and green fluorescence was analyzed by with a SONY 
SH800S Cell Sorter. Because HER2-bound lapatinib is green fluorescent,23 data for persister 
cells were normalized to unstained persister cells, and parental cell data were normalized to 
unstained parental cells. A minimum of 3,000 cells were analyzed for each persister and 
parental replicate. Data were processed with FloJo software.
Iron measurements
Total labile iron (Fe II and Fe III combined) was measured using the colourimetric Iron 
Assay Kit (Abcam) following the manufacturer's instructions. 1.4 million BT474 persister or 
parental cells were tested per replicate for two biological replicate samples. Colourimetric 
signal was read out using a BioTek Synergy 2 Microplate Reader.
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Xenograft experiments
The University of California San Francisco Institutional Animal Care and Use Committee 
(IACUC) approved the xenograft studies in Protocol #AN142193. Tumour size criteria 
permitted a maximum volume of 2000 mm3, however, careful observation of the animals 
and BCS score of 2 or less superseded any laboratory measurement. These limits were not 
exceeded in any experiments. For the formation of xenograft tumours without ferrostatin-1 
(Extended Data Fig. 3h), 10 million A375 GPX4 WT or GPX4 KO (clone 1) cells were 
mixed in a 1:1 PBS:matrigel mixture and injected into the left and right flanks of female 
athymic mice aged 10-12 weeks with a mean body weight of 24 grams (NCR Nude, 
Taconic), respectively. Tumour volume measurements were made twice a week. All mice 
were included in the analysis. For the tumour relapse experiments (Fig. 4d), 10 million A375 
GPX4 WT or KO (clone 1) cells were mixed in a 1:1 PBS:matrigel mixture containing 2.5 
μM ferrostatin-1 and injected into left and right flanks, respectively, of male athymic nude 
mice aged 10-12 weeks with a mean body weight of 25 grams. Mice were dosed daily i.p. 
with 0.2 mg/kg ferrostatin-1 while tumours were initially established and during subsequent 
treatment with 100 mg/kg dabrafenib and 1 mg/kg trametinib twice daily by oral gavage. 
Once tumours had shrunk and tumour volumes stabilized, ferrostatin-1 treatment was ceased 
while dabrafenib and trametinib treatment was continued and tumours relapsed. All mice for 
which any tumour relapsed were included in the analysis.
Statistical analyses
No statistical methods were used to predetermine sample size. For mouse experiments, the 
mice were not randomized. The investigators performing tumour volume measurements 
were blinded. Statistical tests were performed with GraphPad Prism 7.0a. Unless otherwise 
noted, p values were calculated using unpaired, two-tailed t tests assuming unequal variance. 
Graphing of data was performed with GraphPad Prism 7.0a and R v3.2.1.
Data availability
All data are available from the authors upon reasonable request. This manuscript is 
accompanied by four Supplementary tables and data are deposited at the NCBI GEO 
accession GSE84896.
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Extended Data
Extended Data Figure 1. Additional data demonstrating persister cell ferroptosis sensitivity
a, A375 melanoma persister cells are reversibly drug-resistant. Scale bars indicate 400 μm. 
b, Global antioxidant gene-expression is downregulated in BT474 persister cells. P value 
calculated using a two-tailed Wilcoxon signed rank test. c, MCF10A parental cells and d, 
BT474 persister cells derived from carboplatin and paclitaxel were treated with RSL3 or 
ML210 for three days. e, BT474 persister cells or f, parental cells were treated with erastin 
for five days. g, Western blot demonstrating GPX4 knockout in two distinct A375 clones 
(clone 1, KO1; clone 2, KO2). For gel source data, see Supplementary Figure 1. h, BT474 
parental cells co-treated with 2 μM lapatinib and RSL3 or ML210 for three days. Data are 
plotted as means and error bars represent standard deviation. c, n = 3 and d-h, n = 2 
biologically independent samples. c, P value calculated from a two-tailed t test where ns 
represents P > 0.05. All data are representative of two separate experiments.
Extended Data Figure 2. Additional data demonstrating that GPX4 inhibition causes ferroptosis 
in persister cells
A375 persister cells were treated with a, RSL3 or b, ML210 and ferroptosis rescue 
compounds for three days. c, PC9 persister cells were treated with RSL3 or ML210 and 
ferroptosis rescue compounds for three days. d, Relative concentration of total labile iron in 
BT474 parental and persister cells. Data are plotted as means and error bars represent 
standard deviation. a-d, n = 2 biologically independent samples. From two-tailed t tests, *, P 
< 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, P > 0.05. All data are 
representative of two separate experiments.
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Extended Data Figure 3. Additional data demonstrating that persister cells have a disabled 
antioxidant program and depend on GPX4 in vivo
a, Reduced glutathione (GSH) and reduced plus oxidized glutathione (GSH + GSSG) levels 
in BT474 cells. BT474 persister cells were b, treated with RSL3 and antioxidant 
compounds, c, treated with endogenous ROS generating compound DMNQ, or d, treated 
with SOD1 inhibitor LCS-1, for three days. e, ROS levels (DCF stain) in BT474 cells treated 
with ML210 for one hour. f, BT474 persister cells were co-treated with ALDH inhibitor 
disulfiram and ferrostatin-1 for three days. g, Tumour volume measurements for the full time 
course of the experiment presented in Fig. 4d. Ferrostatin-1 was withdrawn on Day 10. See 
source data for individual data points. h, Untreated A375 GPX4 WT or GPX4 KO (clone 1) 
tumour formation without ferrostatin-1 dosing. See source data for individual data points. i, 
Reactive oxygen species levels (DCF stain) in cells regrown without lapatinib for fifteen 
days from BT474 persister cells and then treated with 1 μM RSL3 for one hour. j, Persister 
cell GPX4 dependence model. Data are plotted as means and error bars represent standard 
deviation. a, e, i, n = 3 and b-d, f, n = 2 biologically independent samples, g, n = 4 and h, n 
= 5 animals. From two-tailed t tests, *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 
0.0001; ns, P > 0.05. All data are representative of two separate experiments.
Extended Data Table 1
Expression of EMT and stem markers
RNAseq data for mesenchymal, epithelial and stemness marker genes in BT474 parental and 
persister cells.
Parental Cell FPKM Persister Cell FPKM Fold Change
Mesenchymal
VIM 2.2 37.1 16.9
FN1 0.3 0.6 2.0
ZEB1 0.0 0.0 N/A
ZEB2 0.0 0.0 N/A
TWIST1 2.6 19.9 7.7
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Parental Cell FPKM Persister Cell FPKM Fold Change
TWIST2 0.0 0.0 N/A
SNAI1 1.4 0.4 0.3
SNAI2 0.009 0.04 4.4
CDH2 0.3 1.0 3.0
Epithelial
CDH1 142.8 90.0 0.6
CLDN4 179.4 128.2 0.7
CLDN7 93.2 49.2 0.5
TJP3 26.3 16.1 0.6
MUC1 55.3 42.8 0.8
Sternness
CD133 0.4 1.7 4.3
CD44 2.1 4.6 2.2
Extended Data Table 2
Expression of Nrf2 target genes
RNAseq data for Nrf2 target genes in BT474 parental and persister cells.
Parental Cell FPKM Persister Cell FPKM Fold Change
NRF2 26.1 28.7 1.1
Iron sequestration
FTL 387.3 451.7 1.2
FTH1 736.4 530.0 0.7
HMOX1 2.2 3.9 1.8
HMOX2 23.4 15.8 0.7
Glutathione utilization
GPX2 4.3 1.1 0.3
GSTM1 0.8 1.2 1.4
GSTM2 0.4 2.5 5.6
GSTM3 2.3 3.0 1.3
Quinone detoxification
NQ01 96.7 55.7 0.6
NADPH production
G6PD 50.2 19.4 0.4
PGD 63.3 31.2 0.5
ME1 16.8 5.3 0.3
IDH1 96.4 35.9 0.4
Glutathione production and regeneration
GCLM 4.8 3.4 0.7
GCLC 14.3 16.5 1.2
GSR 70.5 42.8 0.6
SLC7A11 1.6 1.2 0.7
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Parental Cell FPKM Persister Cell FPKM Fold Change
Thioredoxin production, regeneration and utilization
TXN 159.7 105.2 0.7
PRDX1 431.5 293.2 0.7
TXNRD1 25.2 28.4 1.1
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. RNAseq and small-molecule screen in drug-tolerant persister cells
a, A small fraction of BT474 cells enter into a reversible, quiescent drug-tolerant persister 
state in response to nine or more days of treatment with 2 μM lapatinib. Scale bars indicate 
100 μm. b, Small-molecule inhibitor screen in which prederived BT474 persister cells were 
treated with 1 μM small-molecule inhibitors while maintained in 2 μM lapatinib. c, Small-
molecule inhibitor counter-screen in parental BT474 cells. a is representative of two 
independent experiments. b, c, n = 1 biologically independent sample from a single 
screening experiment.
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Figure 2. Persister cells are vulnerable to GPX4 inhibition
Breast (BT474), melanoma (A375), lung (PC9) and ovarian (Kuramochi) cancer parental or 
persister cells (see Methods) were treated with GPX4 inhibitor RSL3 (a-d) or ML210 (e-h) 
for three days. i, A375 GPX4 WT or KO persister cells and j, parental cells with 
ferrostatin-1 withdrawn for three days. Data are plotted as means and error bars represent 
standard deviation. a-h, n = 2, and i, j, n = 3 biologically independent samples. From two-
tailed t tests,*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, P > 0.05. All 
data are representative of two separate experiments.
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Figure 3. GPX4 inhibition causes ferroptosis in persister cells
BT474 persister cells co-treated with RSL3 and a, lipophilic antioxidants ferrostatin-1 and 
liproxstatin-1, b, iron chelator deferoxamine (DFO), c, lipoxygenase inhibitors PD146176 
and NDGA, d, lipid transporter SCP2 inhibitors SCPI-2 and SCPI-4, and e, pan-caspase 
inhibitor Z-VAD-FMK (ZVAD). f, A375 GPX4 KO cells (clone 1) persister cells with 
ferrostatin-1 replaced by ferroptosis rescue compounds or ZVAD. Data are plotted as means. 
a-f, n = 2 biologically independent samples. All data are representative of two separate 
experiments.
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Figure 4. A disabled antioxidant program underlies persister cell sensitivity to ferroptosis
a, Glutathione levels in BT474 cells treated with RSL3 for one hour. b, NADPH levels in 
BT474 cells. c, ROS levels (DCF stain) in BT474 cells treated with RSL3 for one hour. d, 
Relapse of A375 GPX4 WT or KO (clone 1) tumours. Mice bearing GPX4 WT and KO 
tumours on opposing flanks dosed with ferrostatin-1 were treated with dabrafenib and 
trametinib to shrink tumours to their minimal size. Ferrostatin-1 was then withdrawn and 
tumour relapse was monitored. See source data for individual data points. e, left, twenty-four 
hour RSL3 pretreatment of BT474 cells prior to derivation of persister cells, middle, RSL3 
treatment of cells regrown from persister cells upon lapatinib removal for fifteen days, or 
right, two months. Data are plotted as means and error bars represent standard deviation. a, e 
left and middle, n = 3, and b, c, e right, n = 2 biologically independent samples, and d, n = 4 
animals. From two-tailed t tests, *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; 
ns, P > 0.05. All data are representative of two separate experiments.
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